IL3

Across TCGA pan-cancer cohorts, IL3 RNA is linked to patient survival in 13 of 34 cancer types, making it the most broadly survival-associated IL3 data layer compared with 2 for mutation status.

The strongest signal is observed in lung squamous cell carcinoma (LUSC), where higher IL3 RNA is associated with worse disease-free survival. In most high-consensus cancer types, elevated IL3 expression acts as an unfavorable survival marker, although some lineages such as MESO and LAML show a favorable association.

LUSC, MESO, and COAD are the cancer types where IL3 RNA most reproducibly stratifies survival.

RNA survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUSC	DFS	Tertile	II,III,IV	0.340	0.628	.001	72	view →
MESO	DFS	Tertile	III,IV	0.813	0.354	.004	42	view →
COAD	DFS	Tertile	All	0.157	0.578	.002	39	view →
LAML	DFS	Quartile	All	0.616	0.339	.036	12	view →
BLCA	OS	Tertile	IV	0.166	0.586	.030	9	view →
PAAD	OS	Tertile	II,III,IV	0.219	0.451	.043	9	view →
LIHC	OS	Tertile	III,IV	0.563	0.801	.016	9	view →
ESCA	OS	Quartile	All	0.604	0.943	.034	9	view →
PCPG	OS	Tertile	All	0.767	0.958	.013	9	view →
CESC	DFS	Tertile	All	0.796	0.498	.037	6	view →
SCLC	DFS	Tertile	All	0.798	0.454	.038	6	view →
KIRP	DFS	Tertile	All	0.299	0.631	.014	6	view →

Pink = unfavorable, green = favorable. Showing the 12 strongest of 13 lineages.

IL3–LUSC (DFS)

Open the LUSC breakdown →